PIPE-505 : Pipeline Therapeutics initiates phase 1/2a SNHL trial
Pipeline Therapeutics has initiated a phase 1/2a trial of PIPE-505, which is a small molecule gamma secretase inhibitor (GSI), in patients who have sensorineural hearing loss (SNHL) associated with hearing speech in noisy environments. The phase 1/2a trial is anticipated to take in 24 adult patients, and will be carried out as a randomized, double-blind, […]